『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:
  (見出し語句検索:)

登録情報

抽出条件

OWN=閲覧 原田 武志 ([徳島大学.病院.先端医科医療開発研究プロジェクト]/[徳島大学.病院.診療科.内科.血液内科])

登録情報の数

有効な情報: 20件 + 無効な情報: 1件 = 全ての情報: 21件

全ての有効な情報 (20件)
  (見出し語句検索:)

条件追加

[種別](著作の種別)による分類 :
[言語](著作の言語)による分類 :
[カテゴリ](著作のカテゴリ)による分類 :
[共著種別](共著の種別)による分類 :
[学究種別](著作の学究種別)による分類 :
[組織](著作の帰属する組織)による分類 :
閲覧 (未定義) …(20)
[年月日](発行年月日)による分類
○ 年による分類 :
○ 年度による分類 :

抽出結果のリスト

排列順: 項目表示:
閲覧 Takeshi Harada, Shuji Ozaki, Asuka Oda, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Toshio Matsumoto and Masahiro Abe : Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma., International Journal of Hematology, Vol.97, No.6, 743-748, 2013. ...
閲覧 Takeshi Harada, Shuji Ozaki, Asuka Oda, Daisuke Tsuji, Akishige Ikegame, Masami Iwasa, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Yoshiaki Kuroda, Shigeto Kawai, Kouji Itou, Hisafumi Yamada-Okabe, Toshio Matsumoto and Masahiro Abe : Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors, PLoS ONE, Vol.8, No.12, e83905, 2013. ...
閲覧 Takeshi Harada, Teru Hideshima and Kenneth C. Anderson : Histone deacetylase inhibitors in multiple myeloma: from bench to bedside, International Journal of Hematology, Vol.104, No.3, 300-309, Sep. 2016. ...
閲覧 Jana Jakubikova, Danka Cholujova, Teru Hideshima, Paulina Gronesova, Andrea Soltysova, Takeshi Harada, Jungnam Joo, Sun-Young Kong, Raphael E. Szalat, Paul G. Richardson, Nikhil C. Munshi, David M. Dorfman and Kenneth C. Anderson : A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications, Oncotarget, Vol.7, No.47, 77326-77341, 2016. ...
閲覧 Morihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, K. Mehmet Samur, Yu-Tzu Tai, C. Nikhil Munshi, Masahiro Kizaki, Teru Hideshima and C. Kenneth Anderson : Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma, Clinical Cancer Research, Vol.23, No.17, 5225-5237, 2017. ...
閲覧 Takeshi Harada, Ohguchi Hiroto, Grondin Yohann, Kikuchi Shohei, Sagawa Morihiko, Tai Yu-Tzu, Mazitschek Ralph, Hideshima Teru and Anderson C. Kenneth : HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications, The 79th Annual Meeting of the Japanese Society of Hematology, (巻), (号), (頁), Oct. 2017. ...
閲覧 Takeshi Harada, Ohguchi Hiroto, Grondin Yohann, Kikuchi Shohei, Sagawa Morihiko, Tai Yu-Tzu, Mazitschek Ralph, Hideshima Teru and Anderson C. Kenneth : HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications, Leukemia, Vol.31, No.12, 2670-2677, 2017. ...
閲覧 Hiroto Ohguchi, Takeshi Harada, Morihiko Sagawa, Shohei Kikuchi, YT Tai, PG Richardson, Teru Hideshima and KC Anderson : KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival, Leukemia, Vol.31, No.12, 2661-2669, 2017. ...
閲覧 Anamaria Gulla, Teru Hideshima, Giada Bianchi, MT Fulciniti, M Samur Kemal, J Qi, Yu-Tzu Tai, Takeshi Harada, E Morelli, N Amodio, R Carrasco, P Tagliaferri, NC Munshi, P Tassone and C. Kenneth Anderson : Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma, Leukemia, Vol.32, No.4, 996-1002, 2018. ...
閲覧 原田 武志, Oda Asuka, 寺町 順平, Bat-Erdene Ariunzaya, 岩佐 昌美, Maeda Yusaku, 中村 信元, Oura Masahiro, 藤井 志朗, 三木 浩和, 賀川 久美子, Hideshima Teru, Anderson C. Kenneth, 安倍 正博 : HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death, The 43rd Annual Meeting of the Japanese Society of Myeloma, (巻), (号), (頁), 2018年5月. ...
閲覧 Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Oura Masahiro, Shingen Nakamura, Kumiko Kagawa, Okamoto Yasunobu, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe : Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis, The 9th JSH International Symposium 2018 in Kyoto, (巻), (号), (頁), (都市), July 2018. ...
閲覧 Takeshi Harada : Roles of HDAC1 and HDAC3 as therapeutic targets against myeloma cells, The 80th Annual Meeting of the Japanese Society of Hematology, (巻), (号), (頁), Oct. 2018. ...
閲覧 Takeshi Harada, Asuka Oda, Yohann Grondin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masami Iwasa, Masahiro Oura, Shingen Nakamura, Kumiko Kagawa, Yasunobu Okamoto, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe : The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis, 60th ASH Annual Meeting & Exposition, (巻), (号), (頁), San Diego, Dec. 2018. ...
閲覧 原田 武志, Oda Asuka, 天眞 寛文, 寺町 順平, 大浦 雅博, 曽我部 公子, 岩佐 昌美, 藤井 志朗, 三木 浩和, 賀川 久美子, 秀島 輝, Anderson C. Kenneth, 安倍 正博 : The novel therapeutic strategy targeting the HDAC1-IRF4-PIM2 pathway in myeloma cells, The 44th Annual Meeting of the Japanese Society of Myeloma, (巻), (号), (頁), 2019年5月. ...
閲覧 Takeshi Harada, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, C. Kenneth Anderson and Masahiro Abe : Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy, 17th International Myeloma Workshop, (都市), Sep. 2019. ...
閲覧 原田 武志 : 多発性骨髄腫におけるHDACアイソフォームの役割とその選択的阻害による治療法の開発, 第81回日本血液学会学術集会, (巻), (号), (頁), 2019年10月. ...
閲覧 Takeshi Harada, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe : Novel therapeutic rationale for targeting HDAC1 and PIM2 in multiple myeloma, 61th ASH Annual Meeting & Exposition, (巻), (号), (頁), Orlando, Dec. 2019. ...
閲覧 Shuji Ozaki, Takeshi Harada, Hikaru Yagi, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe : Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma, Cancers, Vol.12, No.1, 12, 2019. ...
閲覧 Matthew Ho, Tianzeng Chen, Jiye Liu, Paul Dowling, Teru Hideshima, Li Zhang, Eugenio Morelli, Gulden Camci-Unal, Xinchen Wu, Yu-Tzu Tai, Kenneth Wen, Mehmet Samur, Robert L. Schlossman, Ralph Mazitschek, Emma L. Kavanagh, Sinead Lindsay, Takeshi Harada, Amanda McCann, Kenneth C. Anderson, Peter O'Gorman and Giada Bianchi : Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling, Leukemia, Vol.34, No.1, 196-209, 2020. ...
閲覧 Teru Hideshima, Daisuke Ogiya, Jiye Liu, Takeshi Harada, Keiji Kurata, Jooeun Bae, Walter Massefski and Kenneth C. Anderson : Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways, Leukemia, Vol.in press, No.in press, inpress, 2020. ...

過去3日以内に登録・変更された情報

(なし)

無効な情報 (1件)

閲覧 Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Shingen Nakamura, Hanson Derek, Keiichiro Watanabe, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masami Iwasa, Itsuro Endo, Takeshi Kondo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Yoshiaki Kuroda, Hideaki Horikawa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration, Oncotarget, Vol.7, No.43, 70447-70461, 2016.

本データベースでは情報の登録,保守作業の分散を主たる目的の一つとしております.したがって,上記にリストアップされている情報の保守は個々の情報の当事者に委ねられます.

ある情報を保守する義務があるかないかは,その情報に対して権限を持っているかどうかで判断してください.もちろん情報の所有者が主に管理しなくてはならないことになりますが,権限を持っている利用者が連帯してその情報の保守を行なう義務を負っていると考えてください.

貴方がどの情報について権限を持っているかは,貴方自身の情報を閲覧してください.

Number of session users = 4, LA = 0.47, Max(EID) = 376529, Max(EOID) = 1008393.